John Evans
2021
In 2021, John Evans earned a total compensation of $13.9M as CEO at Beam Therapeutics, a 1,434% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $421,925 |
|---|---|
| Option Awards | $7,336,628 |
| Salary | $590,105 |
| Stock Awards | $5,552,775 |
| Other | $10,542 |
| Total | $13,911,975 |
Evans received $7.3M in option awards, accounting for 53% of the total pay in 2021.
Evans also received $421.9K in non-equity incentive plan, $590.1K in salary, $5.6M in stock awards and $10.5K in other compensation.
Rankings
In 2021, John Evans' compensation ranked 627th out of 12,415 executives tracked by ExecPay. In other words, Evans earned more than 94.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 627 out of 12,415 | 95th |
Division Manufacturing | 209 out of 5,508 | 96th |
Major group Chemicals And Allied Products | 68 out of 2,378 | 97th |
Industry group Drugs | 58 out of 2,099 | 97th |
Industry Biological Products, Except Diagnostic Substances | 21 out of 449 | 95th |
Source: SEC filing on April 22, 2022.
Evans' colleagues
We found two more compensation records of executives who worked with John Evans at Beam Therapeutics in 2021.